Haajira Kaldine
Overview
Explore the profile of Haajira Kaldine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun K, Bhiman J, Tempia S, Kleynhans J, Madzorera V, Mkhize Q, et al.
Nat Med
. 2024 Jul;
30(10):2805-2812.
PMID: 39060660
Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection against symptomatic and severe coronavirus disease 2019. However, much less is known about the efficacy of nAbs in...
2.
Riou C, Bhiman J, Ganga Y, Sawry S, Ayres F, Baguma R, et al.
PLOS Glob Public Health
. 2024 Apr;
4(4):e0002703.
PMID: 38603677
We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of...
3.
Riou C, Bhiman J, Ganga Y, Sawry S, Ayres F, Baguma R, et al.
medRxiv
. 2023 Dec;
PMID: 38045321
Background: We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose...
4.
Motsoeneng B, Manamela N, Kaldine H, Kgagudi P, Hermanus T, Ayres F, et al.
Front Immunol
. 2023 Aug;
14:1231276.
PMID: 37600825
The kinetics of Fc-mediated functions following SARS-CoV-2 infection or vaccination in people living with HIV (PLWH) are not known. We compared SARS-CoV-2 spike-specific Fc functions, binding, and neutralization in PLWH...
5.
Mkhize N, Yssel A, Kaldine H, van Dorsten R, Woodward Davis A, Beaume N, et al.
PLoS Pathog
. 2023 Jun;
19(6):e1011469.
PMID: 37384759
The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016 and 2020 showed for the first time that passively administered broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition against...
6.
Bhiman J, Richardson S, Lambson B, Kgagudi P, Mzindle N, Kaldine H, et al.
Sci Rep
. 2023 Jan;
13(1):1222.
PMID: 36681693
The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination...
7.
Richardson S, Kgagudi P, Manamela N, Kaldine H, Venter E, Pillay T, et al.
Cell Rep Med
. 2023 Jan;
4(1):100910.
PMID: 36603577
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4 and BA.5 variants caused major waves of infections. Here, we assess the sensitivity of BA.4 to binding, neutralization, and antibody-dependent...
8.
Madhi S, Kwatra G, Richardson S, Koen A, Baillie V, Cutland C, et al.
Lancet Infect Dis
. 2022 Oct;
23(3):295-306.
PMID: 36273491
Background: COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before vaccination with...
9.
B Gilbert P, Huang Y, deCamp A, Karuna S, Zhang Y, Magaret C, et al.
Nat Med
. 2022 Aug;
28(9):1924-1932.
PMID: 35995954
The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show...
10.
Kitchin D, Richardson S, van der Mescht M, Motlou T, Mzindle N, Moyo-Gwete T, et al.
Cell Rep Med
. 2022 Apr;
3(3):100535.
PMID: 35474744
The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses...